The page is the record's research on the issuer — no analyst, no rating, no view. # Dermata Therapeutics, Inc. (NASDAQ: DRMA) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Dermata Therapeutics, Inc., listed on NASDAQ under ticker DRMA, with ISIN US2498455045. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Security type is Corporate, sector is 2834 Pharmaceutical Preparations, and jurisdiction is United States, Delaware. Segment is not on the record. Status is listed, not halted. ## The disclosure read The record holds 67 filings across 40 filing days in the window 2025-11-08 to 2026-11-08. The median gap between filing days is 5 days, and the latest filing is 6 days before the record date of 2026-11-08. The latest filing is a regulatory filing dated 2026-11-02. Exchange peers on NASDAQ (4,359 issuers) show a median of 52 filings, a median cadence gap of 6.0 days, and a median latency of 5.0 days. Sector peers in 2834 Pharmaceutical Preparations (526 issuers) show a median of 63.0 filings, a median cadence gap of 6.0 days, and a median latency of 4.0 days. The issuer's filing count of 67 is above the exchange median of 52 and above the sector median of 63.0. ## Auditor The auditor of record is CBIZ CPAs P.C, located in San Diego, California. The record holds one auditor change, dated 2026-02-03. ## Events and halts The record holds one delisting line, dated 2026-08-17. No listing or name change lines are on the record. Domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). Segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag is listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations page. The count is 0. ## Open research No openly published research notes were found. The count is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for this issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001853816.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/DRMA (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/form10-k.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/DRMA (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/DRMA · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp